Rapamycin attenuates atherosclerosis induced by dietary cholesterol in apolipoprotein-deficient mice through a p27Kip1-independent pathway
- 1 January 2004
- journal article
- Published by Elsevier in Atherosclerosis
- Vol. 172 (1) , 31-38
- https://doi.org/10.1016/j.atherosclerosis.2003.09.003
Abstract
No abstract availableKeywords
This publication has 65 references indexed in Scilit:
- Antiproliferative Strategies for the Treatment of Vascular Proliferative DiseaseCurrent Vascular Pharmacology, 2003
- Inflammation and immune responses in atherosclerosisTrends in Immunology, 2002
- Vascular proliferation and atherosclerosis: New perspectives and therapeutic strategiesNature Medicine, 2002
- Innate and acquired immunity in atherogenesisNature Medicine, 2002
- Bench to BedsideCirculation, 2001
- AtherosclerosisNature, 2000
- Atherosclerosis — An Inflammatory DiseaseNew England Journal of Medicine, 1999
- Rapamune® (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progressionClinical Biochemistry, 1998
- Rapamycin-induced inhibition of p34cdc2 kinase activation is associated with G1/S-phase growth arrest in T lymphocytes.Published by Elsevier ,1993
- Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization.The Journal of Antibiotics, 1975